Literature DB >> 20641119

A very high prevalence of low HDL cholesterol in Spanish patients with acute coronary syndromes.

Xavier Pintó1, Jesús Millán, Anna Muñoz, Emili Corbella, Antonio Hernández-Mijares, Manuel Zuñiga, Alipio Mangas, Juan Pedro-Botet.   

Abstract

BACKGROUND: Total and low-density lipoprotein cholesterol (LDL-C) concentrations in coronary artery disease have progressively declined, although high-density lipoprotein cholesterol (HDL-C) has not always been evaluated. The prevalence and related factors of low HDL-C in a cohort of Spanish patients with acute coronary syndromes (ACS) were assessed.
METHODS: Clinical and laboratory data registered at admission and at discharge of 648 patients admitted to coronary care units of 6 Spanish hospitals for ACS between January 2004 and September 2007 were analyzed.
RESULTS: Low HDL-C (HDL-C < 1.04 mmol/L) was observed in 367 (56.6%) patients. Male gender, smoking, hypertension, diabetes, high body mass index, and triglycerides were related to low HDL-C. Female gender was the strongest protective factor against low HDL-C (0.619; 95% confidence interval [CI]: 0.410-0.934; P = 0.022), whereas high triglycerides (1.653; 95% CI: 1.323-2.064; P < 0.001) followed by previous ischemic disease (1.504; 95% CI: 1.073-2.110; P = 0.018) were the strongest factors associated with low HDL-C. One-third of patients were taking statins at admission, but only 2% were on fibrate therapy. A large increase in statin therapy, but not in other hypolipemiant drug therapy, between admission and discharge was noted in the whole cohort and among patients with low HDL-C.
CONCLUSION: Spanish patients with ACS have a very high prevalence of low HDL-C. Male gender, high triglycerides, and previous ischemic disease are strong, independent factors associated with this disorder. As low HDL-C remains almost completely untreated in ACS, strategies to enhance the treatment of this lipoprotein abnormality are urgently required. Copyright (c) 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20641119      PMCID: PMC6653221          DOI: 10.1002/clc.20774

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  6 in total

1.  A Novel Medical Treatment for Lipid Control in Patients with Unstable Angina Pectoris and Statin-Induced Liver Dysfunction.

Authors:  Fang Cui; Youliang Zhang; Qingmin Wei; Cuihua Liu; Junhui Wang; Meng Zhang
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

2.  Prevalence of Conventional Risk Factors and Evaluation of Baseline Indices Among Young and Elderly Patients with Coronary Artery Disease.

Authors:  Arsalan Majeed Adam; Aiman Rehan; Nageen Waseem; Unzela Iqbal; Hira Saleem; Muhammad Armughan Ali; Ali Tariq Shaikh; Ansab Godil
Journal:  J Clin Diagn Res       Date:  2017-07-01

3.  Changes in triglyceride, HDL-C, and non-HDL-C levels in patients with acute coronary syndrome.

Authors:  Péter Koncsos; Péter Fülöp; Imre Juhász; Klára Bíró; László Márk; Gábor Simonyi; György Paragh
Journal:  Wien Klin Wochenschr       Date:  2016-07-05       Impact factor: 1.704

4.  Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East.

Authors:  Khalid Al-Rasadi; Ibrahim Al-Zakwani; Mohammad Zubaid; Amr Ali; Yasser Bahnacy; Kadhim Sulaiman; Wael Al Mahmeed; Jassim Al Suwaidi; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2011-08-30

5.  Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease.

Authors:  Héctor González-Pacheco; Jesús Vargas-Barrón; Maite Vallejo; Yigal Piña-Reyna; Alfredo Altamirano-Castillo; Pedro Sánchez-Tapia; Carlos Martínez-Sánchez
Journal:  Ther Clin Risk Manag       Date:  2014-10-06       Impact factor: 2.423

6.  [Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study].

Authors:  Xavier Pintó; Ferran Trias Vilagut; Joan Rius Taruella; Esther Mairal Sallán
Journal:  Aten Primaria       Date:  2017-06-12       Impact factor: 1.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.